

Bladder Cancer

Diagnosis, Therapeutics, and Management

Edited by

CHERYL T. LEE AND DAVID P. WOOD



Humana Press

Bladder Cancer

Diagnosis, Therapeutics, and Management

Edited by

Charles H. Lee and David H. Abner



© Humana Press

Bladder Cancer

Diagnosis, Therapeutics, and Management

Edited by

Cheryl T. Lee, M.D.

and

David P. Wood, M.D.

Editors:

Cheryl T. Lee, MD
Department of Urology
University of Michigan
Ann Arbor, MI
USA

David P. Wood, MD
Department of Urology
University of Michigan
Ann Arbor, MI
USA

Series Editor

Eric A. Klein, MD
Professor of Surgery
Cleveland Clinic Lerner College of Medicine
Head, Section of Urologic Oncology
Glickman Urological and Kidney Institute
Cleveland, OH

ISBN: 978-1-58829-988-8 e-ISBN: 978-1-59745-417-9
DOI 10.1007/978-1-59745-417-9

Library of Congress Control Number: 2009921444

© Humana Press, a part of Springer Science+Business Media, LLC 2010

All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden.

The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.

While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

springer.com

This book is dedicated to William Joseph Amato, an individual who has contributed greatly to my personal and professional development. He is my friend, my confidant, and my husband.

We also dedicate this book to the memory of Dr. Saroja Adusumilli.

Preface

Bladder cancer continues to be a major disease affecting the healthcare system in the United States, consuming almost \$3 billion annually. Patients at low risk for disease-related death require long-term surveillance because of high recurrence rates. Treatment of intermediate- and high-risk disease requires complex management that is often misapplied due to difficulties in tumor staging and uncertainty about the natural history of non-muscle-invasive cancers. Radical surgery for muscle-invasive disease is underutilized because of concerns about complications, surgical technique, altered quality of life, and diminished reimbursement. Neoadjuvant chemotherapy is rarely incorporated in the management of locally advanced tumors, despite mounting evidence that it offers a modest, but real, survival advantage. Metastatic disease remains a deadly condition, as systemic therapies are largely palliative and not curative. Taken together, there are many challenging hurdles for clinicians when managing patients with this disease. Unfortunately, real progress in improving life expectancy from the disease has been slow.

A fundamental lack of clinical research in the field, coupled with disproportionately low funding from federal and foundation sources, has limited advances in multidisciplinary bladder cancer care. As a result, our practice patterns in 2008 are surprisingly similar to those in '988. In consideration of the major challenges facing patients and providers, we developed this text focused on clinical management. Within *Bladder Cancer: Diagnosis, Therapeutics, and Management*, a group of accomplished authors examine emerging techniques and strategies developed to address common clinical scenarios. Authors provide insight into obstacles to improved survival, discuss methods to

advance the field, and review the related supporting evidence. Our intended goal in creating this text is not to create a summary of bladder cancer, but to spur innovative thoughts and approaches to common problems in the management of early and advanced stage of the disease.

The book consists of four parts addressing diagnostics, surgical technique, and multidisciplinary care. Part I is dedicated to bladder cancer staging, which continues to plague clinicians who unknowingly understage 40–60% of patients. Inaccurate staging greatly undermines therapeutic efficacy and often leaves the patient undertreated. This section particularly focuses on understaging of invasive bladder cancer as well as improved pelvic staging with updated imaging. Part II addresses optimization of treatment for localized disease. Novel approaches to intravesical therapy are discussed, as are specific surgical techniques used to ensure cancer control but also provide improved organ preservation and quality of life. Part III briefly reviews applications of existing systemic therapies in the treatment of locally advanced tumors and metastatic disease. Consideration is given to new types of systemic therapies used in combination with standard drugs to provide a synergistic effect. Finally, Part IV is devoted to a discussion of infrastructure needed to support the translational research efforts that will propel this field forward. Contributors in this and earlier sections represent a mix of seasoned veterans and junior scientists representing the next generation to embrace novel technologies and innovative practice strategies.

Ann Arbor, MI, USA
Ann Arbor, MI, USA

Cheryl T. Lee
David P. Wood

Contributors

Saroja Adusumilli
Department of Radiology, University of Michigan,
Ann Arbor, MI, USA

Tara Allen
Department of Urology, University of Arkansas,
Little Rock, AK, USA

David Berger
Section of Urological Surgery, Kansas University,
Kansas City, KS, USA

Bernard H. Bochner
Division of Urology, Memorial Sloan Kettering
Cancer Center, New York, NY, USA

Stephen Boorjian
Department of Urology, Cornell University,
New York, NY, USA

Deborah Bradley
Division of Hematology-Oncology, University
of Michigan, Ann Arbor, MI, USA

Marta Sanchez-Carbayo
Tumor Markers Group, Spanish National Cancer
Center, Madrid, Spain

Carlos Cordon-Cardo
Department of Pathology, Division of Molecular
Pathology, Columbia University, New York,
NY, USA

Sam S. Chang
Department of Urologic Surgery, Vanderbilt
University, Nashville, TN, USA

Karen Giselle Chee
Division of Hematology-Oncology, University
of California, Davis Cancer Center, Sacramento,
CA, USA

Richard H. Cohan
Department of Radiology, University of Michigan,
Ann Arbor, MI, USA

Jonathon Coleman
Division of Urology, Memorial Sloan-Kettering
Cancer Center, New York, NY, USA

Michael S. Cookson
Department of Urologic Surgery, Vanderbilt
University, Nashville, TN, USA

Matthew R. Cooperberg
Department of Urology, University of California
San Francisco, San Francisco, CA, USA

Guido Dalbagni
Department of Urology, Memorial Sloan Kettering
Cancer Center, New York, NY, USA

Thomas A. Gardiner
Department of Urology, Indiana University,
Bloomington, IN, USA

Scott M. Gilbert
Department of Urology, University of Michigan,
Ann Arbor, MI, USA

Timothy Gilligan
Department of Solid Tumor Oncology, Cleveland
Clinic Clinic Taussig Cancer, Cleveland, OH, USA

Mark. L. Gonzalgo
Department of Urology, Johns Hopkins University
School of Medicine, Baltimore, MD, USA

Graham Greene
Department of Urology, University of Arkansas
for Medical Sciences, Little Rock, AK, USA

H. Barton Grossman
Department of Urology, The University of Texas,
MD Anderson Cancer Center, Houston, TX, USA

Jeffrey M. Holzbeierlein
Section of Urological Surgery, Kansas University,
Kansas City, KS, USA

Hero Hussain
Department of Radiology, University of Michigan,
Ann Arbor, MI, USA

Maha Hussain
Division of Hematology-Oncology, University
of Michigan Medical Center, Ann Arbor, MI, USA

Niels-Erik B. Jacobsen
Department of Urology, Indiana University School
of Medicine, Bloomington, IN, USA

Shida Jin
Clinical Research Informations Systems, University
of Texas, MD Anderson Cancer Center, Houston,
TX, USA

J. Stephen Jones
Glickman Urological Institute, Cleveland Clinic
Foundation, Cleveland, OH, USA

Nicholas Karanikolas
State University of New York, Downstate, Brooklyn,
NY, USA

Badrinath R. Konety
Department of Urology, University of California
San Francisco, San Francisco, CA, USA

Primo N. Lara
Division of Hematology-Oncology, University
of California, Davis Cancer Center, Sacramento,
CA, USA

Jerilyn M. Latini
Department of Urology, University of Michigan,
Ann Arbor, MI, USA

Cheryl T. Lee
Department of Urology, University of Michigan,
Ann Arbor, MI, USA

Ralph Madeb
Department of Urology, University of Rochester,
Rochester, NY, USA

James M. McKiernan
Department of Urology, Columbia University
Medical Center, New York, NY, USA

Edward Messing
Department of Urology, University of Rochester,
Rochester, NY, USA

Randall E. Milikan
Department of Genitourinary Medical Oncology,
University of Texas, MD Anderson Cancer Center,
Houston, TX, USA

Lambda Msezane
Section of Urology, University of Chicago, Chicago,
IL, USA

Matthew E. Nielsen
Department of Urology, Johns Hopkins University
School of Medicine, Baltimore, MD, USA

Phillip M. Pierorazio
Department of Urology, Columbia University
Medical Center, New York, NY, USA

Morand Piert
Department of Radiology, Division of Nuclear
Medicine, University of Michigan, Ann Arbor,
MI, USA

Marcus L. Quek
Department of Urology, Loyola University Stritch
School of Medicine, Maywood, IL, USA

Ganesh V. Raj
Division of Urology, Memorial Sloan Kettering
Cancer Center, New York, NY, USA

Edward M. Schaeffer
Department of Urology, Johns Hopkins University
School of Medicine, Baltimore, MD, USA

Douglas S. Scherr
Department of Urology, New York Presbyterian
Hospital-Weill Cornell University, New York, NY,
USA

Mark P. Schoenberg
Department of Urology, Johns Hopkins University
School of Medicine, Baltimore, MD, USA

Timothy Schuster
Department of Urology, University of Michigan,
Ann Arbor, MI, USA

Stephen Smith
Department of Solid Tumor Oncology, Cleveland
Clinic Foundation, Cleveland, OH, USA

Philippe E. Spiess
Department of Urology, MD Anderson
Cancer Center, Houston, TX, USA

Andrew A. Stec
Department of Urologic Surgery, Vanderbilt
University, Nashville, TN, USA

Gary D. Steinberg
Section of Urology, University of Chicago,
Chicago, IL, USA

Daniel Theodorescu
Department of Medicine, University of Virginia,
Charlottesville, VA, USA

Christopher Y. Thomas
Division of Hematology-Oncology, University
of Virginia, Charlottesville, VA, USA

Alon Z. Weizer
Department of Urology, University of Michigan,
Ann Arbor, MI, USA

Jon M. Willatt
Department of Radiology, University of Michigan,
Ann Arbor, MI, USA

David P. Wood Jr.
Department of Urology, University of Michigan,
Ann Arbor, MI, USA

Michael E. Woods
Department of Urology, Loyola University Stritch
School of Medicine, Maywood, IL, USA

Stuart O. Zimmerman
Clinical Research Informations Systems, University
of Texas, MD Anderson Cancer Center, Houston,
TX, USA

Contents

Preface	vii
Contributors	xiii
 Part I Improving Bladder Cancer Staging	
Section 1 CIS	
1 Approaches to Carcinoma In Situ (CIS)	5
J. Stephen Jones	
2 Fluorescence Cytoscopy	19
Philippe E. Spiess and H. Barton Grossman	
 Section 2 Understaging	
3 Restaging TURBT	27
David Berger and Jeffrey M. Holzbeierlein	
4 Understaging T2: Limitations of Pelvic Imaging	35
Jon M. Willatt and Richard H. Cohan	
5 MRI Endorectal Coil	41
Saroja Adusumilli and Hero Hussain	
6 PET Imaging: Advances in the Detection of Locally Advanced and Nodal Disease	49
Morand Pieri	
7 Detection of Extravesical Disease: A Lack of Bladder Cancer Markers	55
Andrew A. Stec, Michael S. Cookson, and Sam S. Chang	
8 Identification of Nodal Metastases: The role of Iron Oxide Enhanced MRI	67
Bernard H. Bochner	
9 Presence and Significance of Micrometastases	79
Stephen Boorjian and Douglas S. Scherr	
 Part II Optimizing Treatment of Localized Disease	
Section 1 Intravesical Therapy	
10 Perioperative Intravesical Therapy	93
Ralph Madeb and Edward Messing	
11 BCG Refractory Disease	105
Tara Allen and Graham F. Greene	

12	Beyond BCG: Gemcitabine	115
	Ganesh V. Raj and Guido Dalbagni	
13	Beyond BCG: Taxanes	127
	James M. McKiernan and Phillip M. Pierorazio	
Section 2 Cystectomy: Cancer Control and Organ Preservation		
14	Extended Lymph Node Dissection	135
	Michael E. Woods and Marcus L. Quek	
15	Prostate Capsule Sparing Cystectomy	147
	Alon Z. Weizer and Timothy Schuster	
16	Preservation of Reproductive Organs in Women	159
	Lambda Msezane and Gary D. Steinberg	
17	Nerve Sparing Radical Cystectomy	169
	Edward M. Schaeffer, Matthew E. Nielsen, Mark L. Gonzalgo, and Mark P. Schoenberg	
18	Quality of Care Indicators for Radical Cystectomy	177
	Matthew R. Cooperberg and Badrinath R. Konety	
Section 3 Continent Diversion: Problems and Solutions		
19	Continent Diversion: QOL of Orthotopic Diversion vs. Ileal Conduit	191
	Scott M. Gilbert and Cheryl T. Lee	
20	Voiding Dysfunction After Orthotopic Diversion	201
	Jerilyn M. Latini	
21	Overcoming the Stigma of Complications of Continent Cutaneous Diversion	215
	Niels-Erik B. Jacobsen	
Part III Locally Advanced / Distant Disease: Multi-Modality Treatment		
22	Neoadjuvant Chemotherapy: The New Standard	231
	Karen Giselle Chee and Primo N. Lara	
23	Adjuvant Chemotherapy in Bladder Cancer: A Good Concept But Where's the Proof?	239
	Stephen Smith and Timothy Gilligan	
24	Beyond MVAC: New and Improved Chemotherapeutics	247
	Deborah Bradley and Maha Hussain	
Part IV Next Steps: Translational Research		
25	The Role of Microarray Technologies in Bladder Cancer Management	265
	Marta Sánchez-Carbayo and Carlos Córdón-Cardo	
26	Molecular Pathogenesis of Urothelial Carcinoma and the Development of Novel Therapeutic Strategies	277
	Christopher Y. Thomas and Dan Theodorescu	
27	Tools for Study: National Databanking	295
	Randall E. Millikan, Stuart O. Zimmerman, and Shida Jin	

Contents	xi
28 Vaccine Development	303
Nicholas Karanikolas and Jonathan Coleman	
29 Advances in Gene Therapy for Bladder Cancer	311
Niels-Erik B. Jacobsen and Thomas A. Gardner	
Index	325

Part I

Improving Bladder Cancer Staging

Section 1

CIS

1

Approaches to Carcinoma In Situ (CIS)

J. Stephen Jones

Contents

1. Introduction.....	5
2. Pathology	6
3. Endoscopic Diagnosis.....	7
4. “Random” Biopsies.....	7
5. Diagnostic Strategies Following Intravesical Therapy	8
6. Fluorescence Cystoscopy.....	9
7. Molecular Aspects of CIS.....	9
8. Surveillance Strategies.....	10
9. Cystoscopic Surveillance.....	10
10. Urine Cytology.....	11
11. Tumor Markers.....	12
12. Investigational Markers.....	13
13. Management of Tumor Marker Results	14
14. Extravesical Surveillance.....	14
15. Conclusion	15
References.....	15

Abstract Despite its traditional categorization as “superficial,” Carcinoma in situ (CIS) is a high grade, flat, noninvasive bladder cancer confined to the urothelium. Bladder biopsy is required to establish a diagnosis. Cytology to examine voided or bladder wash urine can allow identification of malignant cells, but failure to recognize such cells does not rule out CIS. Options to improve cystoscopic recognition of malignant areas such as fluorescence cystoscopy and narrow band imaging are promising developments. A number of tumor markers have been developed. Most have high sensitivity, but these tests have varying specificity. The urologist must understand the implications of a negative or positive test in order to successfully integrate these tests into clinical practice.

Keywords Carcinoma in situ, Cytology, Cystoscopy, Intravesical therapy, Surveillance

1. Introduction

Malignant urothelial tumors confined to the bladder mucosa are accurately termed nonmuscle invasive instead of being given the traditional “superficial” label (1, 2). The traditional term suggested that all such tumors shared the relatively benign course of low grade papillary tumors. In contrast, patients with highly malignant lesions, including carcinoma in situ (CIS), actually have a serious prognosis if not recognized and treated successfully. CIS is often